Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Spring Investor Summit
 April 1, 2019 -
April 2, 2019
Venue
  Essex House
Hotel
 

Dr. Thomas Adams, CEO and Chairman, and Dr. Mark Erlander, CSO, will be presenting and conducting one-on-one meetings with investors at the Spring Investor Summit on April 1-2 at the Essex House in NYC. This is an exclusive event dedicated to connecting small and micro cap companies with high-level, institutional and retail investors. The Company will be presenting an update of its onvansertib clinical development program and key milestones on Monday, April 1 at 2:00 pm EST.